186 related articles for article (PubMed ID: 38024395)
1. Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents.
Ilyinskii PO; Roy C; Michaud A; Rizzo G; Capela T; Leung SS; Kishimoto TK
PNAS Nexus; 2023 Nov; 2(11):pgad394. PubMed ID: 38024395
[TBL] [Abstract][Full Text] [Related]
2. ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia.
Ilyinskii PO; Michaud AM; Rizzo GL; Roy CJ; Leung SS; Elkins SL; Capela T; Chowdhury A; Li L; Chandler RJ; Manoli I; Andres-Mateos E; Johnston LPM; Vandenberghe LH; Venditti CP; Kishimoto TK
Mol Ther Methods Clin Dev; 2021 Sep; 22():279-292. PubMed ID: 34485611
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles.
Ilyinskii PO; Michaud AM; Roy CJ; Rizzo GL; Elkins SL; Capela T; Chowdhury AC; Leung SS; Kishimoto TK
Sci Adv; 2021 Feb; 7(9):. PubMed ID: 33627416
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease.
Kishimoto TK; Fournier M; Michaud A; Rizzo G; Roy C; Capela T; Nukolova N; Li N; Doyle L; Fu FN; VanDyke D; Traber PG; Spangler JB; Leung SS; Ilyinskii PO
J Autoimmun; 2023 Nov; 140():103125. PubMed ID: 37844543
[TBL] [Abstract][Full Text] [Related]
5. Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.
Kishimoto TK
Front Immunol; 2020; 11():969. PubMed ID: 32508839
[TBL] [Abstract][Full Text] [Related]
6. Circumventing B Cell Responses to Allow for Redosing of Adeno-Associated Virus Vectors.
Ertl HCJ
Hum Gene Ther; 2023 Dec; ():. PubMed ID: 37861281
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles.
Ilyinskii PO; Roy CJ; LePrevost J; Rizzo GL; Kishimoto TK
Front Immunol; 2021; 12():637469. PubMed ID: 34113339
[TBL] [Abstract][Full Text] [Related]
8. Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy.
Weber ND; Odriozola L; Ros-Gañán I; García-Porrero G; Salas D; Argemi J; Combal JP; Kishimoto TK; González-Aseguinolaza G
JHEP Rep; 2023 May; 5(5):100713. PubMed ID: 37096142
[TBL] [Abstract][Full Text] [Related]
9. Successful AAV8 readministration: Suppression of capsid-specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease.
Choi SJ; Yi JS; Lim JA; Tedder TF; Koeberl DD; Jeck W; Desai AK; Rosenberg A; Sun B; Kishnani PS
J Gene Med; 2023 Aug; 25(8):e3509. PubMed ID: 36994804
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Rapamycin and Ibrutinib on Antibody Responses to Adeno-Associated Virus Vector-Mediated Gene Transfer.
Xiang Z; Kuranda K; Quinn W; Chekaoui A; Ambrose R; Hasanpourghai M; Novikov M; Newman D; Cole C; Zhou X; Mingozzi F; Ertl HCJ
Hum Gene Ther; 2022 Jun; 33(11-12):614-624. PubMed ID: 35229644
[TBL] [Abstract][Full Text] [Related]
11. Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia.
Sands E; Kivitz A; DeHaan W; Leung SS; Johnston L; Kishimoto TK
Nat Commun; 2022 Jan; 13(1):272. PubMed ID: 35022448
[TBL] [Abstract][Full Text] [Related]
12. Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses.
Jayandharan GR; Zhong L; Sack BK; Rivers AE; Li M; Li B; Herzog RW; Srivastava A
Hum Gene Ther; 2010 Mar; 21(3):271-83. PubMed ID: 19788390
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and toxicity of AAV gene therapy.
Ertl HCJ
Front Immunol; 2022; 13():975803. PubMed ID: 36032092
[TBL] [Abstract][Full Text] [Related]
14. Blockade of the costimulatory CD28-B7 family signal axis enables repeated application of AAV8 gene vectors.
Frentsch M; Japp AS; Dingeldey M; Matzmohr N; Thiel A; Scheiflinger F; Reipert BM; de la Rosa M
J Thromb Haemost; 2020 May; 18(5):1075-1080. PubMed ID: 32011092
[TBL] [Abstract][Full Text] [Related]
15. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration.
Meliani A; Boisgerault F; Hardet R; Marmier S; Collaud F; Ronzitti G; Leborgne C; Costa Verdera H; Simon Sola M; Charles S; Vignaud A; van Wittenberghe L; Manni G; Christophe O; Fallarino F; Roy C; Michaud A; Ilyinskii P; Kishimoto TK; Mingozzi F
Nat Commun; 2018 Oct; 9(1):4098. PubMed ID: 30291246
[TBL] [Abstract][Full Text] [Related]
16. Adeno-associated virus serotype 1 (AAV1)- and AAV5-antibody complex structures reveal evolutionary commonalities in parvovirus antigenic reactivity.
Tseng YS; Gurda BL; Chipman P; McKenna R; Afione S; Chiorini JA; Muzyczka N; Olson NH; Baker TS; Kleinschmidt J; Agbandje-McKenna M
J Virol; 2015 Feb; 89(3):1794-808. PubMed ID: 25410874
[TBL] [Abstract][Full Text] [Related]
17. A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction.
Nakai H; Thomas CE; Storm TA; Fuess S; Powell S; Wright JF; Kay MA
J Virol; 2002 Nov; 76(22):11343-9. PubMed ID: 12388694
[TBL] [Abstract][Full Text] [Related]
18. Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors.
Giles AR; Govindasamy L; Somanathan S; Wilson JM
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089698
[TBL] [Abstract][Full Text] [Related]
19. Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle.
Ghosh A; Yue Y; Duan D
J Gene Med; 2006 Mar; 8(3):298-305. PubMed ID: 16385549
[TBL] [Abstract][Full Text] [Related]
20. Immune profiling of adeno-associated virus response identifies B cell-specific targets that enable vector re-administration in mice.
Chen M; Kim B; Jarvis MI; Fleury S; Deng S; Nouraein S; Butler S; Lee S; Chambers C; Hodges HC; Szablowski JO; Suh J; Veiseh O
Gene Ther; 2023 May; 30(5):429-442. PubMed ID: 36372846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
